---
document_datetime: 2025-12-02 04:57:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/leqvio.html
document_name: leqvio.html
version: success
processing_time: 0.1133598
conversion_datetime: 2025-12-26 19:06:24.512983
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Leqvio

[RSS](/en/individual-human-medicine.xml/67381)

##### Authorised

This medicine is authorised for use in the European Union

inclisiran Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Leqvio](#news-on)
- [More information on Leqvio](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Leqvio is a medicine used to reduce cholesterol in the blood. It is used in adults with primary hypercholesterolaemia or mixed dyslipidaemia (conditions that cause high levels of fats, including cholesterol, in the blood). It should be used with a low-fat diet.

Leqvio is used in combination with a statin (a type of cholesterol-lowering medicine) when the maximum dose of the statin does not lower cholesterol levels enough. It can also be used in combination with other cholesterol-lowering medicines in patients who cannot take a statin.

Leqvio contains the active substance inclisiran.

Expand section

Collapse section

## How is Leqvio used?

Leqvio is given by injection under the skin, usually in the belly but also in the upper arm or thigh. After the first injection, the next dose is given after 3 months and then it is given every 6 months.

The medicine can only be obtained with a prescription. For more information about using Leqvio, see the package leaflet or contact your doctor or pharmacist.

## How does Leqvio work?

Inclisiran, the active substance in Leqvio, interferes with RNA (genetic material) to limit the production of PCSK9, a protein that can increase levels of LDL-cholesterol ('bad' cholesterol). By preventing PCSK9 production, Leqvio helps to lower LDL-cholesterol levels.

## What benefits of Leqvio have been shown in studies?

Three main studies involving a total of 3,660 patients found Leqvio effective at lowering levels of LDL-cholesterol. Over 94% of patients in the studies were also taking statins or other medicines to lower the levels of lipids (fats) in blood.

The studies included patients with a form of hypercholesterolaemia that runs in families and patients with raised LDL-cholesterol who either had atherosclerotic cardiovascular disease (where fatty deposits have built up in blood vessels) or were prone to atherosclerotic cardiovascular disease. After 510 days (around 15 months), the results were similar for all studies, and overall, LDL-cholesterol had dropped by over 50% in patients treated with Leqvio compared with those receiving placebo (a dummy treatment).

## What are the risks associated with Leqvio?

The most common side effects with Leqvio (which may affect up to 1 in 10 people) are reactions such as pain, redness and rash at the injection site.

For the full list of side effects and restrictions of Leqvio, see the package leaflet.

## Why is Leqvio authorised in the EU?

Studies have found worthwhile reductions in LDL-cholesterol levels in patients treated with Leqvio, which go beyond reductions attained with statins or other lipid-lowering medicines. There is no direct evidence yet that Leqvio reduces heart attacks or stroke but reduction in LDL-cholesterol is linked to reduction in atherosclerotic cardiovascular disease. The side effects of Leqvio are manageable.

The European Medicines Agency therefore decided that Leqvio's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Leqvio?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Leqvio have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Leqvio are continuously monitored. Side effects reported with Leqvio are carefully evaluated and any necessary action taken to protect patients.

## Other information about Leqvio

Leqvio received a marketing authorisation valid throughout the EU on 09 December 2020.

Leqvio : EPAR - Medicine overview

Reference Number: EMA/561767/2020

English (EN) (135.67 KB - PDF)

**First published:** 06/01/2021

[View](/en/documents/overview/leqvio-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-6)

български (BG) (149.66 KB - PDF)

**First published:**

06/01/2021

[View](/bg/documents/overview/leqvio-epar-medicine-overview_bg.pdf)

español (ES) (124.7 KB - PDF)

**First published:**

06/01/2021

[View](/es/documents/overview/leqvio-epar-medicine-overview_es.pdf)

čeština (CS) (148.2 KB - PDF)

**First published:**

06/01/2021

[View](/cs/documents/overview/leqvio-epar-medicine-overview_cs.pdf)

dansk (DA) (124.6 KB - PDF)

**First published:**

06/01/2021

[View](/da/documents/overview/leqvio-epar-medicine-overview_da.pdf)

Deutsch (DE) (127.61 KB - PDF)

**First published:**

06/01/2021

[View](/de/documents/overview/leqvio-epar-medicine-overview_de.pdf)

eesti keel (ET) (113.29 KB - PDF)

**First published:**

06/01/2021

[View](/et/documents/overview/leqvio-epar-medicine-overview_et.pdf)

ελληνικά (EL) (145.52 KB - PDF)

**First published:**

06/01/2021

[View](/el/documents/overview/leqvio-epar-medicine-overview_el.pdf)

français (FR) (125.92 KB - PDF)

**First published:**

06/01/2021

[View](/fr/documents/overview/leqvio-epar-medicine-overview_fr.pdf)

hrvatski (HR) (146.56 KB - PDF)

**First published:**

06/01/2021

[View](/hr/documents/overview/leqvio-epar-medicine-overview_hr.pdf)

italiano (IT) (123.09 KB - PDF)

**First published:**

06/01/2021

[View](/it/documents/overview/leqvio-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (161.78 KB - PDF)

**First published:**

06/01/2021

[View](/lv/documents/overview/leqvio-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (146.39 KB - PDF)

**First published:**

06/01/2021

[View](/lt/documents/overview/leqvio-epar-medicine-overview_lt.pdf)

magyar (HU) (144.72 KB - PDF)

**First published:**

06/01/2021

[View](/hu/documents/overview/leqvio-epar-medicine-overview_hu.pdf)

Malti (MT) (148.9 KB - PDF)

**First published:**

06/01/2021

[View](/mt/documents/overview/leqvio-epar-medicine-overview_mt.pdf)

Nederlands (NL) (124.36 KB - PDF)

**First published:**

06/01/2021

[View](/nl/documents/overview/leqvio-epar-medicine-overview_nl.pdf)

polski (PL) (131.49 KB - PDF)

**First published:**

06/01/2021

[View](/pl/documents/overview/leqvio-epar-medicine-overview_pl.pdf)

português (PT) (125.31 KB - PDF)

**First published:**

06/01/2021

[View](/pt/documents/overview/leqvio-epar-medicine-overview_pt.pdf)

română (RO) (144.92 KB - PDF)

**First published:**

06/01/2021

[View](/ro/documents/overview/leqvio-epar-medicine-overview_ro.pdf)

slovenčina (SK) (148.41 KB - PDF)

**First published:**

06/01/2021

[View](/sk/documents/overview/leqvio-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.29 KB - PDF)

**First published:**

06/01/2021

[View](/sl/documents/overview/leqvio-epar-medicine-overview_sl.pdf)

Suomi (FI) (121.79 KB - PDF)

**First published:**

06/01/2021

[View](/fi/documents/overview/leqvio-epar-medicine-overview_fi.pdf)

svenska (SV) (123.58 KB - PDF)

**First published:**

06/01/2021

[View](/sv/documents/overview/leqvio-epar-medicine-overview_sv.pdf)

Leqvio : EPAR - Risk management plan

English (EN) (4.33 MB - PDF)

**First published:** 06/01/2021

**Last updated:** 04/07/2024

[View](/en/documents/rmp-summary/leqvio-epar-risk-management-plan_en.pdf)

## Product information

Leqvio : EPAR - Product information

English (EN) (502.72 KB - PDF)

**First published:** 06/01/2021

**Last updated:** 18/09/2025

[View](/en/documents/product-information/leqvio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-812)

български (BG) (672.17 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/bg/documents/product-information/leqvio-epar-product-information_bg.pdf)

español (ES) (458.04 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/es/documents/product-information/leqvio-epar-product-information_es.pdf)

čeština (CS) (642.5 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/cs/documents/product-information/leqvio-epar-product-information_cs.pdf)

dansk (DA) (464.45 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/da/documents/product-information/leqvio-epar-product-information_da.pdf)

Deutsch (DE) (462.53 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/de/documents/product-information/leqvio-epar-product-information_de.pdf)

eesti keel (ET) (498.07 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/et/documents/product-information/leqvio-epar-product-information_et.pdf)

ελληνικά (EL) (696.78 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/el/documents/product-information/leqvio-epar-product-information_el.pdf)

français (FR) (614.74 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/fr/documents/product-information/leqvio-epar-product-information_fr.pdf)

hrvatski (HR) (629.67 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/hr/documents/product-information/leqvio-epar-product-information_hr.pdf)

íslenska (IS) (500.23 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/is/documents/product-information/leqvio-epar-product-information_is.pdf)

italiano (IT) (527 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/it/documents/product-information/leqvio-epar-product-information_it.pdf)

latviešu valoda (LV) (622.78 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/lv/documents/product-information/leqvio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (672.11 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/lt/documents/product-information/leqvio-epar-product-information_lt.pdf)

magyar (HU) (663.53 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/hu/documents/product-information/leqvio-epar-product-information_hu.pdf)

Malti (MT) (650.35 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/mt/documents/product-information/leqvio-epar-product-information_mt.pdf)

Nederlands (NL) (497.87 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/nl/documents/product-information/leqvio-epar-product-information_nl.pdf)

norsk (NO) (488.61 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/no/documents/product-information/leqvio-epar-product-information_no.pdf)

polski (PL) (593.28 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/pl/documents/product-information/leqvio-epar-product-information_pl.pdf)

português (PT) (496.35 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/pt/documents/product-information/leqvio-epar-product-information_pt.pdf)

română (RO) (641.37 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/ro/documents/product-information/leqvio-epar-product-information_ro.pdf)

slovenčina (SK) (622.87 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/sk/documents/product-information/leqvio-epar-product-information_sk.pdf)

slovenščina (SL) (595.05 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/sl/documents/product-information/leqvio-epar-product-information_sl.pdf)

Suomi (FI) (481.29 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/fi/documents/product-information/leqvio-epar-product-information_fi.pdf)

svenska (SV) (488.75 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

18/09/2025

[View](/sv/documents/product-information/leqvio-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000247528 30/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Leqvio : EPAR - All authorised presentations

English (EN) (43.72 KB - PDF)

**First published:** 06/01/2021

**Last updated:** 03/05/2022

[View](/en/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-765)

български (BG) (49.94 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/bg/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_bg.pdf)

español (ES) (42.62 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/es/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.55 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/cs/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (45.96 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/da/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (45.12 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/de/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (40.46 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/et/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (46.61 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/el/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_el.pdf)

français (FR) (45.79 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/fr/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (44.48 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/hr/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (44.54 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/is/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.79 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/it/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (46.72 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/lv/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (45.48 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/lt/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (47.54 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/hu/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (46.49 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/mt/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (41.55 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/nl/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (45.42 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/no/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_no.pdf)

polski (PL) (48.55 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/pl/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_pl.pdf)

português (PT) (43.66 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/pt/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_pt.pdf)

română (RO) (45.04 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/ro/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (47.74 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/sk/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.28 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/sl/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (39.99 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/fi/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (44.1 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

03/05/2022

[View](/sv/documents/all-authorised-presentations/leqvio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Leqvio Active substance inclisiran International non-proprietary name (INN) or common name inclisiran Therapeutic area (MeSH)

- Hypercholesterolemia
- Dyslipidemias

Anatomical therapeutic chemical (ATC) code C10AX

### Pharmacotherapeutic group

Lipid modifying agents

### Therapeutic indication

Leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

## Authorisation details

EMA product number EMEA/H/C/005333 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Opinion adopted 15/10/2020 Marketing authorisation issued 09/12/2020 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Leqvio : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (113.11 KB - PDF)

**First published:** 18/09/2025

[View](/en/documents/procedural-steps-after/leqvio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Leqvio : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (143.81 KB - PDF)

**First published:** 16/07/2021

**Last updated:** 18/09/2025

[View](/en/documents/procedural-steps-after/leqvio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Leqvio : EPAR - Public assessment report

Adopted

Reference Number: EMA/696912/2020

English (EN) (4.22 MB - PDF)

**First published:** 06/01/2021

[View](/en/documents/assessment-report/leqvio-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Leqvio

Adopted

Reference Number: EMA/CHMP/520993/2020

English (EN) (143.76 KB - PDF)

**First published:** 16/10/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-leqvio_en.pdf)

#### News on Leqvio

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020) 16/10/2020

#### More information on Leqvio

- [EMEA-002214-PIP01-17-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002214-pip01-17-m02)
- [Leqvio - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/leqvio)

**This page was last updated on** 18/09/2025

## Share this page

[Back to top](#main-content)